COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,304 Articles (22,772 medRxiv, 8,532 bioRxiv)

Most recent first Previous |  Page 1262: Articles 12611-12620  | Next

A Learning Health System Randomized Trial of Monoclonal Antibodies for Covid-19
McCreary, E. K., Bariola, J. R., Minnier, T., Wadas, R. J., Shovel, J. A., Albin, D. L., Marroquin, O. C., Kip, K. E., Collins, K., Schmidhofer, M., Wisniewski, M. K., Nace, D. A., Sullivan, C., Axe, M., Meyer, R., Weissman, A., Garrard, W., Peck-Palmer, O. M., Wells, A., Bart, R. D., Yang, A., Berry, L., Berry, S., McGlothin, A., Crawford, A., Khadem, T., Linstrum, K., Montgomery, S. K., Ricketts, D., Kennedy, J. N., Pidro, C. J., Haidar, G., Snyder, G. M., McVerry, B. J., Seymour, C. W., Angus, D. C., Kip, P. L., Huang, D. T.
10.1101/2021.09.03.21262551 — Posted: 2021-09-09
Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment
Rendeiro, A. F., Vorkas, C. K., Krumsiek, J., Singh, H., Kapadia, S. N., Cappelli, L. V., Cacciapuoti, M. T., Inghirami, G., Elemento, O., Salvatore, M.
10.1101/2021.09.05.21263141 — Posted: 2021-09-09
SARS-CoV-2 infected cells trigger an acute antiviral response mediated by Plasmacytoid dendritic cells in mild but not severe COVID-19 patients
Venet, M., Sa Ribeiro, M., Decembre, E., Bellomo, A., Joshi, G., Villard, M., Cluet, D., Perret, M., Pescamona, R., Paidassi, H., Walzer, T., Allatif, O., Belot, A., trouillet-assant, S., Ricci, E., DREUX, M.
10.1101/2021.09.01.21262969 — Posted: 2021-09-08
SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes
Pawlica, P., Yario, T., White, S., Wang, J., Moss, W., Hui, P., Vinetz, J. M., Steitz, J. A.
10.1101/2021.09.08.459464 — Posted: 2021-09-08
Artemisia annua hot-water extracts show potent activity in vitro against Covid-19 variants including delta
Nair, M. S., Huang, Y., Fidock, D. A., Towler, M., Weathers, P.
10.1101/2021.09.08.459260 — Posted: 2021-09-08
Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses
He, W.-t., Musharrafieh, R., Song, G., Dueker, K., Callaghan, S., Yong, P., Beutler, N., Torres, J. L., Volk, R. M., Zhou, P., Yuan, M., Liu, H., Anzanello, F., Parren, M., Garcia, E., Rawlings, S. A., Smith, D. M., Wilson, I. A., Ward, A. B., Rogers, T., Burton, D. R., Andrabi, R.
10.1101/2021.09.08.459480 — Posted: 2021-09-08
Cigarette smoke preferentially induces full length ACE2 exposure in primary human airway cells but does not alter susceptibility to SARS-CoV-2 infection
Guo, W., Ortmann, B., Crozier, T., Greenwood, E. J., Kottmann, D., Mahadeva, R., Nathan, J. A., Lehner, P. J., McCaughan, F., Porter, L.
10.1101/2021.09.08.459428 — Posted: 2021-09-08
SARS-CoV-2 mRNA vaccination elicits robust and persistent T follicular helper cell response in humans
Mudd, P. A., Minervina, A. A., Pogorelyy, M. V., Turner, J. S., Kim, W., Kalaidina, E., Petersen, J., Schmitz, A. J., Lei, T., Haile, A., Kirk, A. M., Mettelman, R. C., Crawford, J. C., Nguyen, T. H. O., Rowntree, L. C., Rosati, E., Klebert, M. K., Suessen, T., Middleton, W. D., the SJTRC Study Team, , Wolf, J., Teefey, S. A., O'Halloran, J., Presti, R. M., Kedzierska, K., Rossjohn, J., Thomas, P., Ellebedy, A.
10.1101/2021.09.08.459485 — Posted: 2021-09-08 Discussion: Offsite
In silico, In vitro Screening of Plant Extracts for Anti-SARS-CoV-2 Activity and Evaluation of Their Acute and Sub-Acute Toxicity
Damle, L., Damle, H., Ganju, S., C, C., R, B. B.
10.1101/2021.09.07.459230 — Posted: 2021-09-08 Discussion: Onsite
SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis
Hoeg, T. B., Krug, A., Stevenson, J., Mandrola, J.
10.1101/2021.08.30.21262866 — Posted: 2021-09-08 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).